Comprehensive Live-cell Imaging Analysis of Cryptotanshinone and Synergistic Drug-Screening Effects in Various Human and Canine Cancer Cell Lines

Michael L. Bittner^{1,2¶}, Rosana Lopes^{1*¶}, Jianping Hua¹, Chao Sima¹, Aniruddha Datta^{1&}, Heather M. Wilson-Robles^{3&*}

¹Center for Bioinformatics and Genomic Systems Engineering, Texas A&M Engineering Experiment Station, Texas A&M University, College Station, TX, USA

² Translational Genomics Research Institute, Phoenix, AZ, USA.

³College of Veterinary Medicine, Texas A&M University, College Station, TX-77843, USA.

*Corresponding author (s):

Email address: rlopes@tamu.edu

Email address: hwilson@cvm.tamu.edu

¶These authors contributed equally to this work.

&These authors also contributed equally to this work.

ABSTRACT

Background: Several studies have highlighted both the extreme anticancer effects of Cryptotanshinone (CT), a Stat3 crippling component from *Salvia miltiorrhiza*, as well as other STAT3 inhibitors to fight cancer.

Methods: Data presented in this experiment incorporates 2 years of *in vitro* studies applying a comprehensive live-cell drug-screening analysis of human and canine cancer cells exposed to CT at 20 μ M concentration, as well as to other drug combinations. As previously observed in other studies, dogs are natural cancer models, given to their similarity in cancer genetics, epidemiology and disease progression compared to humans.

Results: Results obtained from several types of human and canine cancer cells exposed to CT and varied drug combinations, verified CT efficacy at combating cancer by achieving an extremely high percentage of apoptosis within 24 hours of drug exposure.

Conclusions: CT anticancer efficacy in various human and canine cancer cell lines denotes its ability to interact across different biological processes and cancer regulatory cell networks, driving inhibition of cancer cell survival.

Keywords: cryptotanshinone, *Salvia miltiorrhiza*, STAT3, glioma, osteosarcoma, melanoma, breast cancer

Introduction

The elusive and frequently lethal behavior of cancer cells has led scientists to uncover differing biomolecular pathways and to test novel types of experimental methods in an attempt to cure cancer. Until now, several molecular cell approaches *in vitro* and *in vivo* have been utilized to determine the complex mechanisms by which cancer cells thrive and avoid cell death (1, 2). The complexity of cancer has been highlighted over decades by treatment failure due to evasion of apoptosis, tumor microenvironment modulation, proliferation, metastatic behavior and drugs resistance (3, 4). Despite the fact that human cancer rates are still the leading cause of death in many states in the U.S. Cancer is ranked as the second mortality cause in humans (5, 6). While cancer treatment is far from its desired goal, progress has been achieved by discerning unique models of cancer epidemiology and behavior, increasing preventative care and improving diagnosis (7).

New approaches in treating cancer have evolved since the discovery of specific small molecules that selectively inhibit cell survival, proliferation, and migration in intricate pathways of mutated cancer cells (8,9,10). In the last five years, a particularly useful type of anticancer therapy, that promotes the binding of signal transducer and activator of transcription 3 (STAT3) to Cryptotanshinone has been investigated. This binding tremendously reduces both the cellular production of STAT3, and the availability of the STAT3 dimers that drive production of various cellular oxygen and electron sources (11). Signal transducer and activator of transcriptions (STATs), specially STAT3 and STAT5 are implicated in cancer cell survival, proliferation, migration and apoptosis inhibition (2,12). STAT3 signaling is derived from the Janus Kinase/STAT pathway and it is activated by the assembly of growth factors and cytokines in cell's surface receptors through tyrosine phosphorylation (8,12). Studies have shown that STAT3

nuclear translocation and continuous signaling activation of STAT3 proteins in tumors is achieved by cytoplasmic tyrosine kinase phosphorylation and STAT3 dimerization through Src homology 2 (SH2) domain interaction (8,12,13). In healthy cells, STAT3 protein activation is not constant, it can occur from minutes to hours (12) and can be negatively regulated by phosphatases, inhibitors of cytokine signaling, and protein inhibitor of activated STAT (PIAS) (14). In contrast, increased expression of STAT3 has been found in a variety of cancer cell lines and it is associated with poor disease prognosis and drug resistance (13,15,16). In addition, post-translational modifications of STAT3 with phosphorylation at the serine 727 residue have been observed in the mitochondrial matrix and linked to cell energy metabolism regulation (14,17). Given the importance of STAT3's varied roles in cell metabolism and survival, STAT3 inhibitors have been considered as novel modes of cancer therapy (18,19).

For thousands of years, a well-known Chinese plant, *Salvia miltiorrhiza* (Danshen), has been used to treat cardiovascular (20), gastrointestinal (21), circulatory (22) and neurological (22) diseases. Other benefits of *Salvia miltiorrhiza* include antibacterial (23), immunomodulatory (24) and antioxidant (25) activities. One of the main components of *Salvia miltiorrhiza*, Cryptotanshinone (CT), has been evaluated *in vitro* and *in vivo* as anticancer treatment in human tumor cell lines from different origins, such as, prostate (18,26), breast (26,27,28,29) hepatic (30) and colorectal (18,30,31,32), lung (33), pancreatic (34), kidney (35), glioma (36) and ovarian (37).

To date, several human studies have highlighted significant apoptotic effects of CT treatment in cancer cell lines using concentrations of 5 – 50 μ M (28,32,33,34). Other effects of CT included cell cycle arrest at G1/G0 phase (30,34,38), and at G2/M phase (33,36,39), inhibition of Cyclin D1 protein expression in different types of cancer (18,31,33,34,35), and

downregulation of matrix metalloproteinases (MMP-2/MMP-9), which are responsible for cell invasion and metastasis (37). Human cancer cells exposed to different concentrations of CT showed inhibition of major signaling pathways that are involved in multiple cellular processes such as, mammalian target of rapamycin (mTOR) in hepatic (30), gastric (30), pancreatic (34), soft sarcoma (38) and prostate (38) cancer. Janus kinase 2 (JAK2), phosphoinositide 3-kinase inhibitors/protein kinase B (PI3K/Akt) and extracellular related signal kinases (ERK) signaling was inhibited in pancreatic (34) and liver (1) cancer. The phosphorylation inhibition of STAT3 by CT treatment was reported in prostate (18), pancreatic (34), colorectal cancer (31), gastric (40), renal cell carcinoma (35), and malignant glioma (36).

In dogs and humans, increasing age is associated with higher cancer rates (6,41,42). Recently, dogs have been considered as natural cancer models owing to their fast aging rate, selective breeding, similar environment exposure, and response to treatment comparable to humans (3,43,44,45). Based on genetic classification, epidemiology and disease progression, canine osteosarcoma has a high genetic similarity of that found in children (43,46). Osteosarcoma is one of the most common types of cancer in large breed dogs and ranked within the fourth most common malignancies (44). Mutations on p53 tumor suppressor gene, loss of phosphatase and tensin homolog (PTEN), retinoblastoma (RB1) gene, and STAT3 (47) signaling alterations have been found in dogs and humans diagnosed with osteosarcoma (46,48,49). Similar to osteosarcoma, malignant canine mammary tumors and human breast cancer share similar epidemiology and disease behavior showing breaking point cluster region 1 (BRCA1) mutations and susceptibility to steroid hormones (50). Breast and mammary cancer gene expression analyses found that several genes including PI3K/Akt, KRAS, PTEN, WNT-beta catenin and MAPK pathways were altered in a similar mode in humans and dogs (51). The

mixed mammary cancer type is common in dogs and share similarities with the metaplastic breast cancer in humans (52). Women⁶ and intact female dogs (41,42) have a higher risk to develop mammary and skin cancer which are within the fifth most common types of cancer in both species. Canine malignant melanomas are commonly found in the oral mucosa, contrary to human melanoma that are most commonly observed in the skin. Although derived from different locations human and dog melanomas show aggressive behavior (53). Mutations of PTEN and c-kit are found in both human and dog melanoma (54). Interchangeable benefits can be achieved utilizing anticancer drugs approved by the U.S. Food and Drug Administration (FDA) to treat different types of cancer in humans and dogs (43).

This *in vitro* experiment was designed to establish the timely response of CT drug efficacy alone and combined with single drugs (MLN9708, SH4-54, HO-3867, lapatinib ditosylate, PX-478, paclitaxel, gefitinib, gemcitabine, capecitabine, metformin and cisplatin) in various human and canine cancer cell lines. The main goal in this study is to evaluate the dynamic response of cryptotanshinone alone and its synergistic effects with drug therapies using a live-cell imaging-based assay in human and canine cancer cell lines.

Materials and Methods

Cell lines

All canine cancer cell lines including, ten canine osteosarcoma cell lines (ABRAMS, BKOS, CKOS, MCKOS, SKOS, UWOS-2, MC-KOSA, BW-KOSA, HEIDI, DAISY), six canine malignant melanoma (CML-1, CML6M, 17CM98, JONES, PARKS, KMSA) and two canine mammary cancer cell lines (REM, CMT12) were kindly provided by Dr. Heather M. Wilson-Robles, Small Animal Clinical Sciences Department, College of Veterinary Medicine, Texas

A&M University. All fifty-one human cancer cell lines described in this study were obtained from the Translational Genomics Research Institute, Phoenix, Arizona.

Drugs

All drugs used in this experiment were purchased from Selleckchem, Houston, TX-77014, USA and stored according to manufacturer instructions. Twelve drugs with different concentrations were used in drug-screening analyses including, Cryptotanshinone 20 μ M (STAT3 inhibitor), HO-3867 10 μ M (selective STAT3 inhibitors), SH-4-54 5 μ M (STAT3/STAT5 inhibitor), Paclitaxel 0.1 μ M (microtubule polymer stabilizer), Gefitinib 10 μ M (EGFR inhibitor), PX-478 25 μ M (hypoxia-inducible factor-1 α inhibitor), Lapatinib Ditosylate 5 μ M (EGFR and ErbB2 inhibitor), MLN9708 10 μ M (chymotrypsin-like proteolytic β 5 inhibitor), Metformin 10 mM (mTOR inhibitor), Capecitabine 50 μ M (fluoropyrimidine carbamate), Cisplatin 40 μ M, and Gemcitabine 2 μ M (DNA synthesis inhibitors).

Cell culture and sample preparation

Experiments were performed with various human and canine cancer cell lines from different origins seeded in triplicates over 24 columns in a microtiter plate and analyzed as a group. A total of seven microtiter plates containing fifty-one different human cancer cell lines were analyzed in this experiment. A plate composed by human pancreatic cancer cell lines included five pancreatic carcinomas (PANC1, MIA Paca-2, HS 766T, PANC1 TD2, P4057), two pancreatic adenocarcinomas (HPAF-II, AsPC1), and one pancreatic ductal adenocarcinoma (PL45). A second plate included four breast adenocarcinomas (MCF-7, MDA-MB-231, AU-565, MDA-MB-468), two breast carcinomas (MDA-MB-453, SUM159) and two breast ductal carcinoma cell lines (BT549, BT474). A third plate was formed by six human osteosarcoma cell lines: SaOS-2, 143B,

G292, Hu03N1, HOS, HOS-MNNG, and one fibrosarcoma (HT1080) cell line. The fourth plate included eight human melanoma cancer cell lines (A375, A2058, SK-MEL-28, UACC-257, UACC-903, UACC-1093, UACC1308, UACC-2641) and, the fifth plate was composed by five human glioblastoma cell lines (GBM-12, U87MG, LN-18, LN-229, M059K) and two squamous cell carcinoma (CAL-27, SCC-9) cell lines. Additionally, a plate containing five lung cancer cell lines composed by two non-small cell lung cancer adenocarcinomas (H1975, H2073), a lung carcinoma cell line (A549), and two lung squamous cell carcinomas (SK-MES-1, SW900) was assembled. The last plate contained seven colon cancer cell lines composed by four colorectal adenocarcinomas (HT29, SW480, SW620, COLO205), two colorectal carcinomas (HCT116, LS513), one colon adenocarcinoma (DKS-8), and, one hepatocellular carcinoma cell line (Hep3B).

In addition, three microtiter plates containing eighteen different canine cancer cell lines were analyzed in this experiment. A plate composed by eight canine osteosarcoma cell lines included: ABRAMS, BKOS, CKOS, MCKOS, SKOS, UWOS-2, MC-KOSA and BW-KOSA. A second plate, was composed by six canine malignant melanoma cell lines (CML-1, CML6M, 17CM98, JONES, PARKS, KMSA), one mammary adenocarcinoma (REM) and one mammary carcinoma (CMT12) cell line. The remaining plate was formed by four canine osteosarcoma cell lines (ABRAMS, MCKOS, HEIDI and DAISY), the last two osteosarcoma cell lines had been recently collected from tumor site.

To optimize imaging analyses, a media with low levels of autofluorescence was prepared. The imaging media (IM) contained: 70% M-199 (11825015), 30% RPMI-1640 (11875085) supplemented with 10% FBS (16000044), 20 mM Hepes (15630080), 14 mM Glutamax (35050061), 7 mM of sodium pyruvate (11360070), 1% Penicillin-Streptomycin (15240062), 0.7 g of glucose (A2494001), 0.5 μ M Vybrant® Dye-Cycle™ Violet Stain (V35003) and, CellTox™

Green Cytotoxicity Assay (G8742) at 1:5,000 dilution. The Vybrant® Dye-Cycle™ Violet Stain is a live-cell permeable dye and produces blue fluorescence (< 437 nm) when bound to double-stranded DNA and stimulated by a violet excitation source (< 369 nm). In contrast, the CellTox™ Green Cytotoxicity Assay was incorporated in the media as indicative of cell death. This cyanine dye binds to DNA of cells that show lack of membrane integrity and produces a green fluorescence (< 509 nm) with a 488 nm excitation source.

Preceding the experiment, subconfluent grown cancer cells were dissociated using TrypLE™ Select enzyme (12563029) and resuspended in IM media to establish the number of cells per milliliter in an automated cell counter (C10227). For each experiment, a 30 µl aliquot of each single cell line at density of 75,000 cells/well was delivered to a well in a 384-well microtiter plate (Greiner Bio-One 781091) pre-coated with 10 µg/ml of Rat Tail Collagen Type I (354249). Cells were cultured in the microtiter plate for 20 hours at 37°C in 5% CO₂ incubator prior imaging. The multiple cancer cell line samples were tested in triplicate wells, with a final volume of 60 µl per well in all microtiter plates.

Drug screening and imaging

Phase 1 – Single drug and drug combinations treatment

After each microtiter plate was incubated for 20 hours at 37°C in 5% CO₂, triplicate wells seeded with different cancer cell lines labeled as untreated received an additional 30 µl aliquot of IM media per well and considered as controls. Two-time point images were recorded and saved before adding drugs to each microtiter plate well. Cancer cells were treated in three replicate wells with single drugs and drug combinations. The same amount of IM media (30 µl) containing two times the concentration of a single drug or drug combinations were added to each well in the microtiter plate

rows and mixed by pipetting to all treated cancer cell lines. All experimental drugs were reconstituted in DMSO (D8418) at 10 to 50 mM stock concentration, except for Metformin 10 mM that was diluted in Dulbecco's Phosphate Buffered Saline (02-0119-0500-VWR). Cryptotanshinone 10 mM stocks were frozen at -20°C and prepared fresh every 14 days, other individual drug stock aliquots were stored at -20°C. For each plate, available drugs that have been previously used to treat each specific type of cancer were included to better evaluate the experimental drug responses to different cancer cell lines tested. The single drugs and their concentrations used in this experiment included: Cryptotanshinone 20 µM (STAT3 inhibitor), HO-3867 10 µM (selective STAT3 inhibitors), Paclitaxel 0.1 µM (microtubule polymer stabilizer), Gefitinib 10 µM (EGFR inhibitor), PX-478 25 µM (hypoxia-inducible factor-1α inhibitor), Lapatinib Ditosylate 5 µM (EGFR and ErbB2 inhibitor), MLN9708 10 µM (chymotrypsin-like proteolytic β5 inhibitor), Metformin 10 mM (mTOR inhibitor), Capecitabine 50 µM (fluoropyrimidine carbamate), Cisplatin 40 µM, and Gemcitabine 2 µM (DNA synthesis inhibitors). In addition, Cryptotanshinone at 20 µM concentration was paired with the following single drugs and their respective concentrations: HO-3867 10 µM, PX-478 25 µM were added to all types of cancer; Gefitinib 10 µM and Gemcitabine 2 µM (human pancreatic cancer), Paclitaxel 0.1 µM (breast and canine mammary cancer), Cisplatin 40 µM (human and canine osteosarcoma and human fibrosarcoma), Lapatinib Ditosylate 5 µM (human and canine melanoma, human glioblastoma), MLN9708 10 µM (human glioblastoma and human squamous cell carcinoma), Metformin 10 mM (human lung cancer), and Capecitabine 50 µM (human colorectal and human hepatocellular cancer). Other drug combinations included: MLN9708 10 µM plus SH-4-54 5 µM (STAT3/STAT5 inhibitor), Gemcitabine 2 µM plus HO-3867 10 µM, HO-3867 10 µM plus Paclitaxel 0.1 µM, HO-3867 10 µM plus Cisplatin 40 µM, HO-3867 plus Lapatinib Ditosylate 5 µM, HO-3867 10 µM plus Metformin 10 mM, and HO-3867 10

μM plus Capecitabine 50 μM . A combination of three drug replicates were selected for further testing based on the efficacy of above paired drugs to promote cancer cell death. The composition of drugs delivered in triplicates included: Cryptotanshinone at 20 μM concentration in all combinations plus possible groupings of two other drugs including, HO-3867 10 μM , MLN9708 10 μM , Lapatinib Ditosylate 5 μM , SH-4-54 5 μM , Cisplatin 40 μM and PX-478 25 μM . A triplicate combination of HO-3867 10 μM plus MLN9708 10 μM plus SH-4-54 5 μM drugs was included to each plate. Untreated and treated cells were scanned every hour for 24 hours using an ImageXpress Micro XLS Widefield High-Content Analysis System (Molecular Devices) sampling at three different imaging sites within each well.

Phase II – Assessment of cancer cell survival after drug treatments

The first imaging data of human pancreatic, breast, osteosarcoma, melanoma, glioblastoma, lung, colon, fibrosarcoma, squamous cell carcinoma and, hepatocellular carcinoma cancer cell lines cultured in seven individual plates was performed after 20 hours of incubation at 37°C in 5% CO₂. Canine osteosarcoma, melanoma and mammary cancer cell lines cultured in two individual microtiter plates were kept at the same temperature and time conditions cited above. The ImageXpress Micro XLS Widefield High-Content Analysis System (Molecular Devices) was used to scan three different imaging sites within each well. Two-time points imaging for each cancer cell line run in triplicates were acquired and saved before the addition of drugs and considered as baseline. After the cells received different drugs and their combinations 24-time points imaging were obtained for each triplicate cancer cell line during a 24 hours period. After that, the plate was kept inside the incubator at 37°C in 5% CO₂ for an additional 24 hours and a last time point was imaged and saved for each cancer cell line run in triplicates.

Imaging processing

All images were sent into an in-house pipeline developed in Matlab (Mathworks) using the SDC morphological toolbox (55). After image segmentation on the nuclear channel and green fluorescent channels, a large number of measurements were collected for each individual cell line. Details on the image segmentation method were previously reported (56). Morphological features, nucleus size, nucleus mean intensity, and CellTox TM Green mean intensity in nucleus were used for cell identification as well as cell death classification (57).

RESULTS

The *in vitro* efficacy of CT as anticancer agent has been investigated in cancer cell lines by our laboratory. The strength of our data is enhanced by the wide number of cell lines, different species examined, and the methodology applied with continuous live-cell monitoring in a timely mode improving results accuracy. Moreover, to our knowledge this is the first time CT anticancer effects have been evaluated in canine cancer cell lines in a systematic live-cell imaging-based assay. The main known effect of CT inhibiting cancer cell growth is linked to its capability of inhibiting STAT3 proteins (18,34,35). Although STAT3 proteins are known to be ubiquitous in cells and found in the cytoplasm and mitochondrion, it is not known how the expression of STAT3 in different cancer cells can influence CT anticancer activity (11,16). STAT3 signaling activation stimulates transcription of different oncogenes that will perpetuate cell proliferation, cell survival and resistance to apoptosis (56). Therefore, CT ability to bind to STAT3 proteins will impede STAT3 phosphorylation and subsequently STAT3 signaling

activation (19). Data obtained from this *in vitro* study using a live-cell imaging-based assay showed that CT at 20 μ M concentration was able to induce cell death in various human and canine cancer cell lines. The single CT concentration of 20 μ M utilized in this study was determined based on previous data evaluating cancer cells response to different CT concentrations. Results acquired in our laboratory from several live cancer-cell imaging data found that CT at 20 μ M was effective to induce complete cell death in several cancer cell types (Fig 1). Moreover, no significant changes in percentage of apoptosis in various human cancer cells examined was observed with CT concentrations above 20 μ M (Fig 2). The cell death time in hours was attributed to each type of cancer when the percentage rate of cell death reached 80 % in the majority of cancer cell lines exposed to CT (Table 1). The fastest rate that CT at 20 μ M induced cell death was observed in human fibrosarcoma and hepatocellular carcinoma (12 hours), followed by canine melanoma (13 hours) (Fig 3), human melanoma (16 hours), human glioblastoma, human squamous cell carcinoma (Fig 4a) and canine osteosarcoma (17 hours) (Fig 4b), human osteosarcoma (18 hours), human breast (Fig 5) and human lung cancer (20 hours), human colorectal cancer (22 hours) (Fig 6), human pancreatic and canine mammary cancer (24 hours). In addition, CT at 20 μ M concentration induced cell death in two recently collected canine osteosarcoma cell lines at 16 hours of incubation. Similar findings were observed in canine osteosarcoma cell lines with higher passage numbers.

Figure 1, Cell Death Response Curve for a variety of Human Cancers. Cell death response expressed in percentage of apoptosis in fourteen human cancer cell lines exposed to CT at 20 μ M concentration. Cancer cell lines are represented by colored lines : colorectal cancer (103N- black, 49N- red, HCT116-orange, HT29- light blue, SW480- gray), melanoma (A2058- royal blue, A375- green), squamous cell carcinoma (CAL27- neon green), glioblastoma (GBM12- brown),

lung adenocarcinoma (H2073- pink), pancreatic adenocarcinoma (HPAC- dark green),
hepatocellular carcinoma (Hep3B- maroon), breast adenocarcinoma (MCF7- sky blue), breast
carcinoma (MDA-MB-453- light green)

Figure 2, Cell Death Response Curve for a variety of Human Cancers. Cell death response
expressed in percentage of apoptosis in fourteen human cancer cell lines exposed to CT at 50 μ M
concentration. Cancer cell lines are represented by colored lines : colorectal cancer (103N- black,
49N- red, HCT116- pink, HT29- dark green, SW480- light green), melanoma (A2058- royal
blue, A375- green), squamous cell carcinoma (CAL27- purple), glioblastoma (GBM12- neon
green), lung adenocarcinoma (H2073- brown), pancreatic adenocarcinoma (HPAC- orange),
hepatocellular carcinoma (Hep3B- light blue), breast adenocarcinoma (MCF7- maroon), breast
carcinoma (MDA-MB-453- sky blue)

Figure 3, Cell Death Response Curve for Canine Melanoma. Cell death response expressed in
percentage of apoptosis in canine melanoma cell lines exposed to CT at 20 μ M concentration
(CML1- black line, CML6M- red line, 17CM98- blue line, PARKS- purple line, KMSA- neon
green line).

Figure 4, Cell Death Response Curves for Glioblastoma and Canine Osteosarcoma. 4a –
Cell death response expressed in percentage of apoptosis in human glioblastoma (GBM12- red
line, U87MG- blue line, LN18- dark green line, LN229- purple line, M059K - neon green line)
and squamous cell carcinoma cell lines (CAL27- black line, SCC9- pink line) exposed to CT at
20 μ M concentration. 4b – Cell death response expressed in percentage of apoptosis in canine

osteosarcoma cell lines exposed to CT at 20 μ M concentration (ABRAMS- black line, BKOS- red line, CKOS- blue line, MCKOS- dark green line, SKOS- purple line, UWOS-2- neon green line, MCKOSA- brown line, BWKOSA- pink line)

Figure 5, Cell Death Response Curves for Human Breast Cancer. Cell death response expressed in percentage of apoptosis in human breast cancer cell lines exposed to CT at 20 μ M concentration (MCF7- black line, MDA-MB-231- red line, MDA-MB-453- blue line, AU565- dark green line, SUM159- purple line, MDA- MB-468- neon green light, BT549- brown line, BT474- pink line)

Figure 6, Cell Death Response Curves for Human Colorectal Cancer. Cell death response expressed in percentage of apoptosis in human colorectal cancer cell lines exposed to CT at 20 μ M concentration (HCT116- black line, HT29- red line, SW480- blue line, SW620- dark green line, COLO205 - purple line, LS513- neon green line, DSK8- brown line)

Table

Table 1- Time response in hours (h) to cell death induced by single drug and drug combinations screening in different human and canine cancer cell lines using a live-cell imaging-based assay

Single drug and drug combinations Cell lines	CT	CT + HO-3867	CT + MLN9708	CT + MLN9708 + SH-4-54	CT + HO-3867 + SH-4-54	CT + HO-3867 + Lapatinib Ditosylate	CT + HO-3867 + PX-478 / Gefitinib
Breast cancer	20 h	17 h	-		-	-	18 h

							(PX478)
Canine Mammary cancer	24 h	15 h	-	16 h	-	10 h	13 h (PX478)
Human Colorectal cancer	22 h	20 h	-	17 h	-	-	-
Human Fibrosarcoma	12 h	-	-	10 h	-	11 h	-
Human Glioblastoma	17 h	16 h	16 h	13 h	11 h	14 h	-
Human Hepatocellular Carcinoma	12 h	8 h	-	9 h	8 h	8 h	9 h (PX478)
Human Lung cancer	20 h	13 h	-	11 h	13 h	12 h	11 h (PX478)
Human melanoma	16 h	11 h	-	13 h	11 h	9 h	13 h (PX478)
Canine melanoma	13 h	12 h	-	12 h	12 h	-	-
Human osteosarcoma	18 h	15 h	-	10 h	8 h	11 h	13 h (PX478)
Canine osteosarcoma	17 h	13 h	-	11 h	10 h	11 h	13 h (PX478)
Recently collected canine osteosarcoma cell lines	16 h	-	-	-	15 h	-	-
Human Pancreatic cancer	24 h	20 h	-	-	-	19 h	14h(Gefitinib) 19 h (PX478)
Human Squamous Cell Carcinoma	17 h	-	12 h	12 h	-	-	-

CT- Cryptotanshinone (20 μ M), HO-3867 (10 μ M), MLN9708 (10 μ M), SH-4-54 (5 μ M),
Lapatinib Ditosylate (5 μ M), PX-478 (25 μ M), and Gefitinib (10 μ M)

The comprehensive and systematic drug-screening analyses of 51 human and 18 canine live-cancer cell imaging-based assay revealed the synergistic and dynamic response to CT treatment in several cancer cell lines. Results obtained from all human and canine cancer cell lines showed a remarkable decrease in cell death time in all types of cancer when selected drugs were combined to CT at 20 μ M concentration (Table 1). The time in hours represent the point in

time that most cancer cells achieved at least 80 % percentage of apoptosis in several types of human and canine cancer exposed to a variety of drug concentrations. The drug-screening analyses shown in this study suggests that recently collected canine osteosarcoma cell lines required a longer time of exposure to selected drug combinations to induce cell death response.

Drug efficacy measured by percentage of apoptosis

The percentage values of cell death were determined using a live-cell imaging-based dynamic response trajectory (57). This live-cancer cell imaging technology provides hourly measurements of continuous imaging sets from each cancer cell, seeded in a 384-well microtiter plate, to closely monitor the characteristic changes in cell morphology in a timeline mode. Moreover, to accurately discriminate between live and dead cells, live-cell fluorescent dyes were incorporated in the growth media to ultimately determine the percentage of cell death enhancing our capabilities. Drug efficacy in this study was measured by the power of CT and selected drug combinations to induce cell death. The ability to monitor different cancer cell types every hour for 24 hours or more, emphasizes the strength of utilizing a drug-screening methodology using a live-cell imaging-based assay. CT and selected drug combinations showed a percentage of apoptosis between 96% to 100% in human osteosarcoma (Fig 7a), and 98% to 100% in canine osteosarcoma cell lines (Fig 7b). In both species, treated cells reached the maximum percentage of apoptosis in an average of 12.5 hours. However, cells from recently collected canine osteosarcoma, treated with CT and selected drug combinations displayed an average of 15.5 hours to reach maximum percentage of apoptosis. A rate of 92% to 100% percentage of apoptosis in glioblastoma cell lines was observed within an average of 14.5 hours of incubation with CT and selected drug combinations (Fig 8). Human melanoma cells treated with CT and

selected drug combinations showed 98% to 100% apoptosis, and canine melanoma cell lines had 92% to 100% percentage of apoptosis. In both species melanoma cell death was observed at an average of 12.25 hours of incubation. However, canine melanoma cancer cells did not show similar cell death response to a few drug combinations compared to human melanoma (Table - 1). Human lung cancer showed an average of 13.3 hours of incubation to achieve 98% to 100% percentage of apoptosis exposed to CT and selected drug combinations (Fig 9). A higher time with an average of 19.7 hours of exposure to CT and selected drug combinations was required for human colon cancer cells to achieve a maximum percentage of apoptosis of 90% to 100%. Human breast cancer and canine mammary cancer showed 91% to 100% maximum percentage of apoptosis in response to CT and selected drug combinations at an average of 18.3 and 15.6 hours, respectively. Human pancreatic cancer showed a 90% to 100% maximum percentage of apoptosis in response to CT and selected drug combinations at an average of 19.2 hours of exposure to drugs (Fig 10). The single cell lines human fibrosarcoma, hepatocellular carcinoma and squamous cell carcinoma examined in this study displayed a 98% to 100% percentage of apoptosis in response to CT and selected drug combinations at an average of 11, 9, and 13.7 hours, respectively.

Figure 7, Cell Death Response Curves in Human and Canine Osteosarcoma. 7a Cell death response expressed in percentage of apoptosis in human osteosarcoma cell lines (SaOS- black line, 143B- red line, G292- blue line, Hu03N1- dark green line, HOS- purple line, HOS-MNNG- neon green line) exposed to CT at 20 μ M, HO-3867 at 10 μ M, and SH-4-54 at 5 μ M concentration. 7b Cell death response expressed in percentage of apoptosis in canine osteosarcoma cell lines (ABRAMS- orange line, BKOS- dark green line, CKOS- light blue line, MCKOS- maroon line, SKOS- sky blue line, UWOS-2- neon green line, MCKOSA- gray line,

BWKOSA- light green line) exposed to CT at 20 μ M, HO-3867 at 10 μ M, and SH-4-54 at 5 μ M concentration

Figure 8, Cell Death Response Curves for Human Glioblastomas. Cell death response expressed in percentage of apoptosis in human glioblastoma cell lines (GBM12- black line, U87MG- red line, LN18- blue line, LN229- green line, M059K- purple line) exposed to CT at 20 μ M, HO-3867 at 10 μ M, and SH-4-54 at 5 μ M concentration

Figure 9, Cell Death Response Curves for Human Lung Tumors. Cell death response expressed in percentage of apoptosis in human lung cancer cell lines (H1975- red line, H2073- purple line, A549- neon green line, SKMES1- orange line, SW900- dark green line exposed to CT at 20 μ M , HO-3867 at 10 μ M, and PX-478 at 25 μ M concentration

Figure 10, Cell Death Response Curves for Pancreatic Cancer. Cell death response expressed in percentage of apoptosis in human pancreatic cancer cell lines (PANC1- black line, MIA Paca-2- red line, HS766T- blue line, PANC1 TD2- dark green line, P4057- purple line, PL45- neon green line, AsPC1 - brown line, HPAF- pink line) exposed to CT at 20 μ M, HO-3867 at 10 μ M, and Gefitinib at 10 μ M concentration

Cancer cells response to drug-screening was assessed by changes in cell morphology combined to intensity of fluorescent dyes and compared to untreated cancer cell lines. The cell nucleus size and nucleus mean intensity analyzed using a blue live-cell dye in untreated cancer cells revealed a homogeneously stained nucleus. In contrast, cells exposed to CT and drug

combinations displayed increasing nucleus condensation in a timeline fashion. Cell death was determined by measuring CellTox™ Green (CTG) mean intensity in the cell nucleus as result of cancer cell membrane rupture and binding of CTG dye to DNA. Increased CTG nucleus intensity and pyknosis is a typical characteristic of cell death.

DISCUSSION

Although several *in vitro* studies have demonstrated the anticancer properties of CT in human cancer cells, we present here a reproducible and comprehensive live-cancer cell imaging-based assay that investigates drug efficacy in different species. The first objective in the present study, was to determine the response of CT using an *in vitro* live-cell imaging-based assay in human and canine cancer cell lines. The second objective, was to investigate the synergistic effects of CT and drug combinations utilizing the same methodology in human and canine cancer cell lines. This is the first time CT anticancer effects have been evaluated in canine cancer cells in a systematic live-cell imaging-based assay. Findings emphasize that CT at 20 μ M concentration can induce cell death in the majority of human and canine cancer cells examined within 24 hours of drug exposure. Moreover, CT in combination with other single drugs including, HO-3867, MLN9708 or paired drugs such as, MLN9708 plus SH-4-54, HO-3867 plus SH-4-54, HO-3867 plus Lapatinib, and HO-3867 plus Gefitinib or PX-478 produced synergistic effects observed by further decreasing cell death time in different types of cancer.

The efforts being applied in this study are aimed at ceasing to continue the enormous number of struggles to build up cancer treatments based on simply attempting testing of endless numbers of chemicals and proteins, to hopefully find sets which can be applied to a cancer patient to sufficiently eliminate the cancer's disruption of the patient's survival. A very clear

demonstration of how a biological logician could concentrate on discerning what and how cellular components keep shifting in response to an organism's continuous management of its bodily components was described by Waddington (59). In this line of thought, one of the most important issues in the fight against cancer is blocking the components required for cancer cell life. As cancer cells can exhibit a reservoir of highly active STAT3, it seems as though STAT3 can act as the essential director of the required fueling operations for cells that are carrying out extreme survival activities. A very direct way to test this is to apply a drug, or drugs, that can inactivate STAT3's actions, and determine rates of death of those cancer cells reliant on high levels of STAT3. While it has taken considerable time for efforts to design effective STAT3 inhibitors, a small number of effective inhibitors have been produced in the last seven years. STAT3 protein can become very effective in sponsoring the production and canalization of its own two protein domain combined form, as well as the combined forms of other proteins that also support cellular oxygenation. Alternatively, if STAT3 production is not high, what STAT3 is available may be further less active due to formation of a STAT3 and CT joint product. CT is a protein that Chinese researchers extracted from plant root systems which will readily bind to STAT3. This will block the formation of other oxygenating products based on STAT3:CT providing another way of eradicating cancer cells.

Based on our results, four types of human cancer cell lines exposed to CT treatment including, pancreatic, breast, lung and colorectal cancer cells showed an increased time to attain cell death. Similar observations were found in canine mammary cancer, and recently collected canine osteosarcoma cells from naturally occurring disease. Recent genetic classification of various canine tumors (46,47,50,52,54) show that similar to humans, cancers in dogs are also known to have an invasive behavior and show resistance to drugs. In the present study, canine

osteosarcoma, human osteosarcoma and glioblastoma cell lines, exhibited similar response to single CT treatment and cancer cell death was further enhanced by introducing another STAT3/5 inhibitor, a proteasome inhibitor drug, and an EGFR/ErbB2 inhibitor. Up-regulated STAT3 signaling has been previously found in human and canine osteosarcoma cell lines, and the effects of a small molecule inhibitor that prevented STAT3/DNA interaction, and further STAT3 cancer cell's transcription has been documented (47). Similarly, it has been observed that glioma-initiating cells proliferation, and tumor growth are intrinsically linked to STAT3 up-regulation (17). A significant decrease in cell death time to 13 hours in all human glioblastoma cells analyzed *in vitro* was observed in this study using a combination of CT, a proteasome inhibitor drug, and a STAT3/5 inhibitor. Abnormal proteasome activation has been associated to excess of unfolded protein response and subsequently endoplasmic reticulum distress (60). A further increase in glioblastoma cell's death was observed when CT, a selective STAT3 inhibitor, and other STAT3/5 inhibitor were combined reducing the cell death time to 11 hours. These results confirm previous reports (17,36) suggesting that activated STAT3 response is one of altered signaling pathways involved in the proliferation and survival of tumor cells in human gliomas. In general, several factors influence treatment of brain tumors *in vivo*, starting with the blood brain barrier that contributes to decreased drug delivery efficacy needed to induce cancer cell death. Nonetheless, significant tumor reduction size and increased survival time in mouse presenting human glioma orthotopic xenograft was previously observed after CT treatment (36). Therefore, human and canine osteosarcoma, and human glioma cells showed increased cell death response when exposed to STAT3 inhibitor drugs.

Hypoxia inducible factor 1- alpha (HIF-1 α) up-regulation is involved in cancer cell proliferation, metastasis, resistance to therapy and worse prognosis (61). HIF-1 α is known to

induce low oxygen levels found in the tumor microenvironment, mainly in solid tumors. In addition, overexpression of (HIF-1 α), has been found to be regulated by STAT3 signaling (15). Several cancer cell lines examined in this study, including human hepatocellular carcinoma, lung cancer, breast and canine mammary cancer, human and canine osteosarcoma, human melanoma and pancreatic cancer showed a consistent and quick cell death response when a HIF-1 α was combined to CT and a selective STAT3 inhibitor. Moreover, results in this experiment show remarkable synergistic effects observed in pancreatic cancer cells treated with selective STAT3 inhibitors, an EGFR/ErbB2 inhibitor, and a HIF-1 α inhibitor. Pancreatic cancer treated with CT, a selective STAT3 inhibitor, and Gefitinib (EGFR inhibitor) also showed encouraging results with the lowest time capable of inducing cell death in all eight pancreatic cancer cells examined. Similar synergistic effects *in vitro* and *in vivo* have been reported in ovarian cancer with a combination of Gefitinib and a JAK/STAT3 inhibitor drug (62).

Findings obtained in the present study revealed that cell death in seven human colorectal cancer, and eight human breast cancer cell lines exposed to CT at 20 μ M concentration, occurred at 22, and 20 hours, respectively. In contrary, a previous report indicated that CT at a 20 μ M concentration induced cell death to human breast carcinoma (MCF-7) cells within 72 hours of drug exposure (26). The reason for several hours of delay in breast cancer cell death in the prior study could be attributed to different methodology applied, drug composition, and drug delivery procedures. Synergistic effects showing a decrease from 20 to 17 hours in cell death time was observed in all human breast cancer cell lines when a selective STAT3 inhibitor was combined to CT. Similar to previous data in human and canine cancer cell lines, adding a selective STAT3 inhibitor reduced colorectal cancer cell's death from 22 to 20 hours. Previous *in vitro* study in colorectal cancer cells treated with CT showed decreased cell invasion, and *in vivo* CT treatment

decreased colorectal cancer tumor size, promoted downregulation of PI3K/Akt/mTOR signaling and inhibition of HIF-1 α factor (63). It has been observed that STAT3 signaling is responsible for up-regulation of HIF-1 α , and both activated pathways lead to cell proliferation, metastasis, drug resistance and poor prognosis (15,61). It is also well known that CT induce STAT3 inhibition (31,36) and several reports have demonstrated CT inhibitory effects on major cancer signaling pathways in pancreatic cancer (34), and cholangiocarcinoma¹ cells. Moreover, inhibition of PI3K/Akt/mTOR pathway has also been observed in ER-negative breast cancer cells (Bcap37) treated with CT at low concentration (29) and ER α -positive breast cancer cells (28). Results in the present study from *in vitro* human pancreatic, glioblastoma, colorectal cancer, osteosarcoma and canine osteosarcoma cells treated with CT at 20 μ M concentration, and drug combinations corroborate findings from various reports showing CT anticancer properties. In the same way, our results confirm that canine mammary cancer cells showed an equivalent response to CT treatment, and the addition of a selective STAT3 inhibitor enhanced cell death emphasizing the biological and genetic resemblance to human breast cancer (51).

CT anticancer effects have also been analyzed *in vitro* and *in vivo* in human non-small cell lung cancer (NSCLC) at different CT concentrations (10 to 40 μ g/ml) and found that exposure to higher CT concentrations showed reduction in lung cancer size and cell's survival time (63). Results in the present study confirm CT anticancer effects at 20 μ M concentration and cell death was observed after 20 hours of drug exposure in human lung cancer cell lines. Related findings from *in vitro* and *in vivo* studies in lung adenocarcinoma cells showed cancer cell growth inhibition and decrease in tumor xenograft size by CT at different concentrations (33). In addition, similar to our observations, the latest study reported no significant differences in cancer cell growth inhibition increasing CT concentrations above 20 μ M concentration. Human and

dogs with melanoma have shown alterations in similar signaling pathways including RAS/MAPK, PI3K/Akt, and mTOR (53). Although RAS mutations in canine melanoma have not been frequently found in spontaneous disease (65), human and canine melanoma cells in the present study showed a similar response to CT and drug combinations. Moreover, recent *in vitro* report in human melanoma cells have shown that CT concentrations of 1.25 to 20 μ M were capable to induce apoptosis (39).

Little is known about CT absorption, metabolism and its bioavailability in humans and animals (66, 67). A low CT concentration percentage of 6.7 and 11.1 have been measured after oral dose in rats and dog's plasma samples, respectively. However, detection of CT and metabolites in concentrations of 32 to 191 times higher have been found mainly in stomach, intestine, lung, and liver after oral treatment with CT formulated in an inclusion-complex form (66). Higher concentrations of CT and metabolites after intravenous injection also was observed in lungs and liver (66). The increased CT concentrations found in selected organs including, stomach, intestine, lung and liver indicate that these organs can be the first-line targets to test CT anticancer properties in naturally occurring disease in dogs. Evaluation of CT bioavailability and CT plasma concentrations in healthy human subjects was assessed using a micronized granule powder technology leading to higher CT plasma concentrations compared to traditional CT plant extraction (67). In addition, low cytotoxicity effects were found in healthy human cell lines exposed to CT (68).

Data presented in this study emphasizes the importance of *in vitro* experiments to identify the response from single drugs and drug combinations according to each cancer cell type. Cancer complexity can be addressed by utilizing synergistic drug combinations leading to a speedy cell death rate minimizing cancer cells' capabilities of invasion, metastasis and stemness behavior.

Nonetheless, *in vivo* testing is invaluable to determine dosage, drug efficacy and possible side effects triggered by anticancer drugs candidates. The long history of benefits from *Salvia miltiorrhiza* associated with CT, countless *in vitro* and *in vivo* reports of anticancer efficacy, and inhibition of several major cancer signaling pathways, suggests that CT has great potential as anticancer drug.

REFERENCES

1. Ke, F., Wang, Z., Song, X., Ma, Q., Hu, J., Jang, L., Zhang, Y., Liu, Y., Zhang, Y., Gong, W. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFkB pathways in cholangiocarcinoma cells. *Drug Des., Develop and Therapy* **11**, 1753-1766 (2017).
2. Yue, P., Lopez-Tapia, F., Paladino, D., Li Y., Chen, C.-H., Namanja, A.T., Hilliard, T., Chen Y., Tius, M.A., Turkson, J. Hydroxamic acid and benzoic acid-based STAT3 inhibitors suppress human glioma and breast cancer phenotypes *in vitro* and *in vivo*. *Cancer Res.* **76**, 652-663 (2016).
3. Sorenmo, K.U., Kristiansen, V.M., Cofone, M.A., Shofer, F.S., Breen, A.-M., Langeland, M., Mongil, C.M., Grondahl, A.M., Teige, J., Goldschmidt, M.H. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. *Vet. and Comp. Oncol.* **7**, 3, 162-172 (2009).
4. Canadas, A., Santos, M., Nogueira, A., Assis, J., Gomes, M., Lemos, C., Medeiros, R., Dias-Pereira, P. (2018). Canine mammary tumor risk is associated with polymorphisms in *RAD51* and *STK11* genes. *J. Vet. Diag. Invest.* **30**, 733-738.

580 5. Heron, M., Anderson, R.N. Changes in the leading cause of death: recent patterns in heart
581 disease and cancer mortality. *N.C.H.S. Data Brief* **254**, 1-8 (2016).

582 6. Siegel, R.L., Miller, K.D., Jemal, A. Cancer statistics, 2019. *CA. Cancer J. Clin.* **69**, 7-34
583 (2019).

584 7. Cavero, I. 2012 Annual meeting of the safety pharmacology society: spotlight on targeted
585 oncology medicines. *Expert Opinion on Drug Safety* **12**, 589-603 (2013).

586 8. Yu, C.-L., Meyer, D.J., Campbell, G.S., Larner, A.C., Carter-Su, C., Schwartz, J., Jove, R.
587 Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by Src
588 oncoprotein. *Science* **269**, 81-83 (1995).

589 9. Cash, H., Shah, S., Moore, E., Caruso, A., Uppaluri, R., Waes, C.V., Allen, C. mTOR and
590 MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in
591 syngeneic models of oral cavity cancer. *Oncotarget* **6**, 36400-36417 (2015).

592 10. Juvekar, A., Hu, H., Yadegarynia, S., Lyssiotis, C.A., Ullas, S., Lien, E.C., Bellinger, G.,
593 Son, J., Hok, R.C., Seth, P., Daly, M.B., Kim, B., Scully, R., Asara, J.M., Cantley, L.C., Wulf,
594 G.M. Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
595 *PNAS* E4338-E4347 (2016).

596 11. Gough, D.J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A.C., Levy, D.E.
597 Mitochondrial Stat3 supports Ras-dependent oncogenic transformation. *Science* **26**, 1713-1716
598 (2009).

599 12. Buettner, R., Mora, B., Jove, R. Activated STAT signaling in human tumors provides novel
600 molecular targets for therapeutic intervention. *Clinical Cancer Res.* **8**, 945-954 (2002).

13. Assumpção, A.L.F.V., Jark, P.C., Hong, C.C., Lu, Z., Ruetten, H.M., Heaton, C.M., Pinkerton, M.E., Pan, X. STAT3 expression and activity are up-regulated in diffuse large B cell lymphoma of dogs. *J. Vet. Intern. Med.* **32**, 361-369 (2018).
14. Camporeale, A., Demaria, M., Monteleone, E., Giorgi, C., Wieckowski, M.R., Pinton, P., Poli, V. STAT3 activities and energy metabolism: dangerous liaisons. *Cancers* **6**, 1579-1596 (2014).
15. Carpenter, R.L. & Lo, H.-W. Stat3 targets genes relevant to human cancers. *Cancers* **6**, 897-925 (2014).
16. Cui, X., Jing, X., Yi, Q., Long, C., Tan, B., Li, X., Chen, X., Huang, Y., Xiang, Z., Tian, J., Zhu, J. Systematic analysis of gene expression alterations and clinical outcomes of STAT3 in cancer. *Oncotarget* **9**, 3198-3213 (2018).
17. Ganguly, D., Fan, M., Yang, C.H., Zbtek, B., Finkelstein, D., Roussel, M.F., Pfeffer, L.M. The critical role that Stat3 plays in glioma-initiating cells: Stat3 addiction glioma. *Oncotarget* **9**, 22095-22112 (2018).
18. Shin, D.S., Kim, H.N., Shin, K.D., Yoon, Y.J., Kim, S.J., Han, D.C., Kwon, B.M. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. *Cancer Res.* **69**, 193–202 (2009).
19. Furtek, S.L., Matheson, C.J., Backos, D.S., Reigan, P. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors. *Oncotarget* **7**, 77998-78008 (2016).
20. Cheng, T.O. Cardiovascular effects of Danshen. *Internat. J. Cardiol.* **121**, 9-22 (2007).

21. Wang, B.E. Treatment of chronic liver diseases with traditional Chinese medicine. *J. Gastroenterol. Hepatol.* **15**, SE67-E70 (2000).
22. Yu, X.-Y., Lin, S.-G., Chen, X., Zhou, Z.-W., Liang, J., Duan, W., Chowbay, B., Wen, J.-Y., Chan, E., Cao, J., Li, C.-G., Zhou, S.-F. Transport of cryptotanshinone, a major active triterpenoid in *Salvia Miltiorrhiza Bunge* widely used in the treatment of stroke and Alzheimers disease, across the blood-brain barrier. *Cur. Drug Metab.* **8**, 365-377 (2007).
23. Lee, J.-W., Ji, Y.-J., Lee, S.-O., Lee, I.-S. Effect of *Salvia Miltiorrhiza Bunge* on antimicrobial activity and resistant gene regulation against Methicillin-Resistant-*Staphylococcus aureus* (MRSA). *J. Microbiol.* **45**, 350-357 (2007).
24. Wei, W.-J., Zhou, P.-P., Lin, C.-J., Wang, W.-F., Li, Y., Gao, K. Diterpenoids from *Salvia Miltiorrhiza* and their immune-modulating activity. *J. Agric. Food Chem.* **65**, 5985-5993 (2017).
25. Tu, Q., Wang, R., Ding, B., Zhong, W., Cao, H. Protective and antioxidant effect of Danshen polysaccharides on cerebral ischemia/reperfusion injury in rats. *Int. J. Biol. Macromol.* **60**, 268-271 (2013).
26. Chen, W., Liu, L., Luo, Y., Odaka, Y., Awate, S., Zhou, H., Shen, T., Zheng, S., Lu, Y., Huang, S. Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells. *Cancer Prev. Res.* **5**, 778-787 (2012).
27. Zhou, J., Xu, X.-Z., Hu, Y.-R., Hu, A.-R., Zhu, C.-L., Gao, G.-S. Cryptotanshinone induces inhibition of breast tumor growth by cytotoxic CD4⁺ cells through the JAK2/STAT4/ perforin pathway. *Asian Pac. J. Cancer Prev.* **15**, 2439-2445 (2014).
28. Li, S., Wang, H., Hong, L., Liu, W., Huang, F., Wang, J., Wang, P., Zhang, X., Zhou, J. Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling. *Cancer Biol. Ther.* **16**, 176-184 (2015a).

29. Liu, X., Pan, L., Liang, J., Li, J., Wu, S. Cryptotanshinone inhibits proliferation and induces apoptosis via mitochondria-derived reactive oxygen species involving FOXO1 in estrogen-receptor-negative breast cancer Bcap37 cells. *Royal S. Chem.* **6**, 22232-22243 (2016).
30. Park, I.-J., Yang, W.K., Nam, S.-H., Hong, J., Yang, K.R., Kim, J., Kim, S.S., Choe, W., Kang, I., Ha, J. Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma. *Apoptosis* **19**, 615-628 (2014).
31. Li, W., Saud, M., Young, M.R., Colburn, N.H., Hua, B. Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth *in vitro*. *Mol. Cell Biochem.* **406**, 63-73 (2015b).
32. Xu, Z., Jiang, H., Zhu, Y., Wang, H., Jiang, J., Chen, L., Xu, W., Hu, T., Cho, C.H. Cryptotanshinone induces ROS-dependent autophagy in multidrug resistant colon cancer cells. *Chem.-Biol. Inter.* **273**, 48-55 (2017).
33. Chen, L., Wang, H.J., Xie, W., Yao, Y., Zhang, Y.S., Wang, H. Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells *in vitro* and *in vivo*. *Mol. Med. Rep.* **9**, 2447-2452 (2014).
34. Ge, Y., Yang, B., Chen, Z., Cheng, R. Cryptotanshinone suppresses the proliferation and induces the apoptosis of pancreatic cancer cells via the STAT3 signaling pathway. *Mol. Med. Rep.* **12**, 7782-7788 (2015).
35. Chen, Z., Zhu, R., Zheng, J., Chen, C., Huang, C., Ma, J., Xu, C., Zhai, W., Zheng, J. Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma. *Oncotarget* **8**, 50023-50033 (2017).

- 668 **36.** Lu, L., Zhang, S., Li, C., Zhou, C., Li, D., Liu, P., Huang, M., Shen, X. Cryptotanshinone
669 inhibits human glioma cell proliferation *in vitro* and *in vivo* through SHP-2-dependent inhibition
670 of STAT3 activation. *Cell Death and Dis.* **8**, e2767 (2017).
- 671 **37.** Jiang, G., Liu, J., Ren, B., Zhang, L., Owusu, L., Liu, L., Zhang, J., Tang, Y., Li, W. Anti-
672 tumor and chemosensitization effects of Cryptotanshinone extracted from *Salvia miltiorrhiza*
673 *Bge.* on ovarian cancer cells *in vitro*. *J. Ethnopharmacol.* **205**, 33-40 (2017).
- 674 **38.** Chen, W., Luo, Y., Liu, L., Zhou, H., Xu, B., Han, X., Shen, T., Liu, Z., Lu, Y., Huang, S.
675 Cryptotanshinone inhibits cancer cell proliferation by suppressing mammalian target of
676 rapamycin-mediated cyclin D1 expression and Rb phosphorylation. *Cancer Prev. Res.* **3**, 1015–
677 1025 (2010).
- 678 **39.** Ye, T., Zhu, S., Zhu, Y., Feng, Q., He, B., Xiong, Y., Zhao, L., Zhang, Y., Yu, L., Yang, L.
679 Cryptotanshinone induces melanoma cancer cells apoptosis via ROS-mitochondrial apoptotic
680 pathway and impairs cell migration and invasion. *Biom. & Pharmacot.* **82**, 319-326 (2016).
- 681 **40.** Wang, J., Zhang, G., Dai, C., Gao, X., Wu, J., Shen, Li, Chen, Z., Liu, P. Cryptotanshinone
682 potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3
683 activity. *J. Intern. Med. Res.* **45**, 200-230 (2016).
- 684 **41.** Merlo, D.F., Rossi, L., Pellegrino, C., Ceppi, M., Cardellino, U., Capurro, C., Ratto, A.,
685 Sambucco, P.L., Sestito, V., Tanara, G., Bocchini, V. Cancer incidence in pet dogs: findings of
686 the animal tumor registry of Genoa, Italy. *J. Vet. Med.* **22**, 976-984 (2008).
- 687 **42.** Grüntzig, K., Graf, R., Boo, G., Guscetti, F., Hassig, M., Axhausen, K.W., Fabrikant, S.,
688 Welle, M., Meier, D., Folkers, G., Pospischil A. Swiss canine cancer registry 1955-2008:
689 occurrence of the most common tumour diagnoses and influence of age, breed, body size, sex
690 and neutering status on tumour development. *J. Comp. Path.* **155**, 156-170 (2016).

43. Paolini, M., Davis, S., Lana, S., Withrow, S., Sangiorgi, L., Picci, P., Hewitt, S., Triche, T., Meltzer, P., Khanna, C. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. *B.M.C. Genomics* **10**, 1-13 (2009).

44. Fenger, J.M., London, C.A., Kisseberth, W.C. Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology. *I.L.A.R. J.* **55**, 69-85 (2014).

45. Regan, D., Garcia, K., Thamm, D. Clinical, pathological, and ethical considerations for the conduct of clinical trials in dogs with naturally occurring cancer: a comparative approach to accelerate translational drug development. *I.L.A.R.* 1-12 (2019).

46. Gustafson, D.L., Duval, D.L., Regan, D.P., Thamm D.H. Canine sarcomas as surrogate for the human disease. *Pharmacol. & Therapeutics* **188**, 80-96 (2018).

47. Fossey, S.L., Liao, A.T., McCleese J.K., Bear, M.D., Lin, J., Li, P.-K., Kisseberth, W.C., London, C.A. Characterization of Stat3 activation and expression in canine and human osteosarcoma. *B.M.C.* **9**, 1-15 (2009).

48. Levine, R.A., Fleischli, M.A. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. *Vet. Pathol.* **37**, 54-61 (2000).

49. Loukopoulos, P., Thorton, J.R., Robinson, W.F. Clinical and pathologic relevance of p53 index in canine osseous tumor. *Vet. Pathol.* **40**, 237-248 (2003).

50. Im, K.-S., Kim, I.-H., Kim, N.-H., Lim, H.-Y., Kim, J.-H., Sur, J.-H. Breed-related differences in altered BRCA1 expression, phenotype and subtype in malignant canine mammary tumors. *The Vet. J.* **195**, 366-372 (2013).

51. Uva, P., Aurisicchio, L., Watters, J., Loboda, A., Kulkarni, A., Castle, J., Palombo, F., Viti, V., Mesiti, G., Zappulli, V., Marconato, L., Abramo, F., Ciliberto, G., Lahm, A., La Monica, N.,

713 de Rinaldis, E. Comparative expression pathway analysis of human and canine mammary
714 tumors. *BMC* **10**, 1-20 (2009).

715 **52.** Saad, E.S., Milley, K.M., Al-Khan, A.A., Nimmo, J.S., Bacci, B., Tayebi, M., Day, M.J.,
716 Richardson, S.J., Danks, J.A. Canine mixed mammary tumor as a model for human breast cancer
717 with osseous metaplasia. *J. Comp. Path.* **156**, 352-365 (2017).

718 **53.** Simpson, R.M., Bastian, B.C., Michael, H.T., Webster, J.D., Prasad, M.L., Conway, C.M.,
719 Prieto, V.M., Gary, J.M., Goldschmidt M.H., Esplin, D.G., Smedley, R.C., Piris, A., Meuten, D.J.,
720 Kiupel, M., Lee, C.-C., Ward, J.M., Dwyer, J.E., Davis, B.J., Anver, M.R., Molinolo, A.A.,
721 Hoover, S.B., Rodriguez-Canales, J., Hewitt, S.M. Sporadic naturally occurring melanoma in dogs
722 as a preclinical model for human melanoma. *Pigment Cell Melanoma Res.* **27**, 37-47 (2013).

723 **54.** Murakami, A., Mori, T., Sakai, H., Murakami, M., Yanai, T., Hoshino, Y., Maruo, K.
724 Analysis of Kit expression and Kit exon 11 mutations in canine oral malignant melanomas. *Vet.*
725 *Comp. Oncol.* **9**, 219-224 (2011).

726 **55.** Dougherty, E.R. & Lotufo, R.A. *Hands-on morphological image processing*. Infobase
727 Publishing eBooks. Web. 9 Apr. 2019. <http://spie.org/Publications/Book/501104?SSO=>
728 (Bellingham Spie Press Book, Washington, 2003).

729 **56.** Hua, J., Sima, C., Cypert, M., Gooden, G., Shack, S., Alla, L., Smith, E., Trent, J.M.,
730 Dougherty, E.R., Bittner, M.L. Tracking transcriptional activities with high-content
731 epifluorescent imaging. *J. Biomed. Optics* **17**, 046008-1-15. (2012).

732 **57.** Sima, C., Hua, J., Cypert, M., Miller, T., Wilson-Robles, H.M., Trent, J.M., Dougherty E.R.,
733 Bittner, M.L. Assessing combinational drug efficacy in cancer cells by using image-based dynamic
734 response analysis. *Cancer Informatics* **14**, 33-43 (2015).

58. Demaria, M., Camporeale, A., Poli, V. Stat3 and metabolism: how many ways to use a single molecule? *Intern. J. Cancer* **135**, 1997-2003 (2014).
59. Waddington, C.H. Canalization of Development and the inheritance of Acquired Characters. *Nature* **3811**, 563-565 (1942).
60. Lub, S., Maes, K., Menu, E., De Bruyne, E., Vanderkerken, K., Valckenborgh, E.V. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. *Oncotarget* **7**, 6521-6532 (2015).
61. Koh, M.Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R.R., Kirkpatrick, D.L., Powis, G. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor -1 α . *Mol. Cancer Ther.* **7**, 90-100 (2008).
62. Wen, W., Wu, J., Liu, L., Tian, Y., Buettner, R., Hsieh, M.-Y., Horne, D., Dellinger, T.H., Han, E.S., Jove, R., Yim, H.J. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. *Mol. Cancer* **14**, 1-1 (2015).
63. Zhang, X., Luo, W., Zhao, W., Lu, J., Chen, X. Isocryptotanshinone induced apoptosis and activated MAPK signaling in human breast cancer MCF-7 cells. *J. Breast Cancer* **18**, 112-118 (2015).
64. Ye, Y.T., Zhong, W., Sun, P., Wang, D., Wang, C., Hu, L.M., Qian, J.Q. Apoptosis induced by the methanol extract of *Salvia miltiorrhiza* Bunge in non-small cell lung cancer through PTEN-mediated inhibition of PI3K/Akt pathway. *J. Ethnopharmacol.* **200**, 107-116 (2017).
65. Escobar, H.M., Günther, K., Richter, A., Soller, J.T., Winkler, S., Nolte, I., Bullerdiek J. Absence of Ras-gene hot spot mutations in canine fibrosarcomas and melanomas. *Anticancer Res.* **24**, 3027-3028 (2004).

- 757 **66.** Pan, Y., Bi, H.-C., Zhong, G.-P., Chen, X., Zuo, Z., Zhao, L.-Z., Gu, L.-Q., Liu, P.-Y.,
758 Huang, Z.-Y., Zhou, S.-F., Huang, M. Pharmacokinetic characterization of hydroxyl- β -
759 cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug
760 purified from Danshen (*Salvia miltiorrhiza*). *Xenobiotica* **38**, 382-398 (2008).
- 761 **67.** Xing, L., Tan, Z.-R., Cheng, J.-L., Huang, W.-H., Zhang, W., Deng, W., Yuan, C.-S., Zhou,
762 H.-H. Bioavailability and pharmacokinetic comparison of tanshinones between two formulations
763 of *Salvia miltiorrhiza* in healthy volunteers. *Scientific Reports* **7**, 1-10 (2016).
- 764 **68.** Mannelli, L.D.C., Piccolo, M., Maione, F., Ferraro, M.G., Irace, C., Feo, V.D., Ghelardini, C.,
765 Mascolo, N. Tanshinones from *Salvia miltiorrhiza* Bunge revert chemotherapy-induced neuropathic
766 pain and reduce glioblastoma cells malignancy. *Biomed. & Pharmacotherapy* **105**, 1042-1049
767 (2018).

Figure 1

Figure 2

Figure 3

bioRxiv preprint doi: <https://doi.org/10.1101/2020.06.30.179887>; this version posted June 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 4

Figure 5

Figure 6

bioRxiv preprint doi: <https://doi.org/10.1101/2020.06.30.179887>; this version posted June 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 7

Figure 8

Figure 9

bioRxiv preprint doi: <https://doi.org/10.1101/2020.06.30.179887>; this version posted June 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure10